Advertisement

Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas

  • Chongxian Hou
  • Yukitomo Ishi
  • Hiroaki Motegi
  • Michinari Okamoto
  • Yafei Ou
  • Jiawei Chen
  • Shigeru YamaguchiEmail author
Laboratory Investigation

Abstract

Purpose

Overexpression of CD44 has been detected in many types of tumor tissues. Moreover, CD44 is recognized as a cancer stem cell marker for many cancers. However, the prognostic value of CD44 for glioma patients has not yet been clarified. The authors tried to explore the impact of CD44 expression on grade II/III glioma patients.

Methods

To assess the RNA expression levels of CD44 in glioma tissues and normal brain tissues, meta-analyses were conducted in the online Oncomine database. The mRNA expression levels of CD44, CD44s, and CD44v2–v10 in 112 grade II/III glioma patients in Hokkaido University Hospital (HUH) were detected by qPCR. The RNA-seq data and clinical data of grade II/III glioma patients were obtained from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases.

Results

Based on the Oncomine database, CD44 has significantly high expression in glioma tissues as compared with normal tissues. We explored the clinical relevance of CD44 mRNA expression based on the HUH cohorts, the TCGA cohorts, and the CGGA cohorts. In survival analysis, high mRNA expression of CD44 was correlated with poor overall survival and poor progression-free survival in grade II/III glioma patients. Multivariate Cox regression analyses confirmed CD44 as an independent prognostic factor for grade II/III glioma patients.

Conclusions

The present study suggests that overexpression of CD44 is associated with a poor prognosis for grade II/III glioma patients. Moreover, our findings suggest that CD44 could serve as a prognostic biomarker in grade II/III glioma patients.

Keywords

CD44 Glioma Prognostic factor Biomarker 

Notes

Acknowledgements

We would like to thank Mr. Xie Tao for the English language review.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

The present study was approved by the local Ethics Committee at Hokkaido University Hospital (Sapporo, Japan; 015–0154). As this study was retrospective, informed consent was waived by the IRB. All procedures performed in the present study were in accordance with 1964 Helsinki Declaration and its later amendments.

Supplementary material

11060_2019_3288_MOESM1_ESM.tif (1.9 mb)
Oncomine microarray database was used to evaluate the mRNA expression of CD44 in glioma tissues vs. normal brain tissues. a Nine microarray datasets containing 18 groups regarding mRNA expression of CD44 in glioma tissues vs. normal brain tissues were involved in this meta-analysis. b A meta-analysis of five microarray datasets containing ten groups regarding mRNA expression of CD44 in grade II/III glioma tissues vs. normal brain tissues. c A meta-analysis of six microarray datasets containing six groups regarding mRNA expression of CD44 in GBM tissues vs. normal brain tissues. d Box plots derived from gene expression data of each group comparing expression of CD44 in glioma tissues and normal brain tissues are shown. Data are shown as a median rank of CD44 through each dataset analysis. The P value for CD44 was presented using the median ranked analysis about glioma vs. normal tissues—Supplementary Fig. 1 (TIFF 1934 kb)
11060_2019_3288_MOESM2_ESM.tif (931 kb)
The correlation between CD44 mRNA expression and OS of glioma patients. a–c The association between CD44 mRNA expression and OS in grade II gliomas. d–f The association between CD44 mRNA expression and OS in grade III gliomas. g–i The association between CD44 mRNA expression and OS in IDH mutant gliomas. j–l The association between CD44 mRNA expression and OS in IDH wild type gliomas—Supplementary Fig. 2 (TIFF 931 kb)
11060_2019_3288_MOESM3_ESM.docx (25 kb)
Supplementary Tables (DOCX 25 kb)

References

  1. 1.
    Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:iv1–iv86.  https://doi.org/10.1093/neuonc/noy131
  2. 2.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996.  https://doi.org/10.1056/NEJMoa043330 CrossRefGoogle Scholar
  3. 3.
    Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS (2015) The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 15:741–752.  https://doi.org/10.1586/14737175.2015.1051968 CrossRefGoogle Scholar
  4. 4.
    Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45.  https://doi.org/10.1038/nrm1004 CrossRefGoogle Scholar
  5. 5.
    Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4:528–539.  https://doi.org/10.1038/nrc1391 CrossRefGoogle Scholar
  6. 6.
    Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI (2008) Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18:288–295.  https://doi.org/10.1016/j.semcancer.2008.03.005 CrossRefGoogle Scholar
  7. 7.
    Prochazka L, Tesarik R, Turanek J (2014) Regulation of alternative splicing of CD44 in cancer. Cell Signal 26:2234–2239.  https://doi.org/10.1016/j.cellsig.2014.07.011 CrossRefGoogle Scholar
  8. 8.
    Chen C, Zhao S, Karnad A, Freeman JW (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64.  https://doi.org/10.1186/s13045-018-0605-5 CrossRefGoogle Scholar
  9. 9.
    Dosio F, Arpicco S, Stella B, Fattal E (2016) Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 97:204–236.  https://doi.org/10.1016/j.addr.2015.11.011 CrossRefGoogle Scholar
  10. 10.
    Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, Cuartas I, Raventos C, Martinez-Ricarte F, Poca MA, Garcia-Dorado D, Lahn MM, Yingling JM, Rodon J, Sahuquillo J, Baselga J, Seoane J (2010) TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655–668.  https://doi.org/10.1016/j.ccr.2010.10.023 CrossRefGoogle Scholar
  11. 11.
    Wang F, Zheng Z, Guan J, Qi D, Zhou S, Shen X, Wang F, Wenkert D, Kirmani B, Solouki T, Fonkem E, Wong ET, Huang JH, Wu E (2018) Identification of a panel of genes as a prognostic biomarker for glioblastoma. EBioMedicine 37:68–77.  https://doi.org/10.1016/j.ebiom.2018.10.024 CrossRefGoogle Scholar
  12. 12.
    Nishikawa M, Inoue A, Ohnishi T, Kohno S, Ohue S, Matsumoto S, Suehiro S, Yamashita D, Ozaki S, Watanabe H, Yano H, Takahashi H, Kitazawa R, Tanaka J, Kunieda T (2018) Significance of glioma stem-like cells in the tumor periphery that express high levels of CD44 in tumor invasion, early progression, and poor prognosis in glioblastoma. Stem Cells Int 2018:5387041.  https://doi.org/10.1155/2018/5387041 CrossRefGoogle Scholar
  13. 13.
    Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke H, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346.  https://doi.org/10.1016/j.ccr.2013.08.001 CrossRefGoogle Scholar
  14. 14.
    Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I (2011) CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 6:e24217.  https://doi.org/10.1371/journal.pone.0024217 CrossRefGoogle Scholar
  15. 15.
    Pietras A, Katz AM, Ekstrom EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC (2014) Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14:357–369.  https://doi.org/10.1016/j.stem.2014.01.005 CrossRefGoogle Scholar
  16. 16.
    Tsidulko AY, Kazanskaya GM, Kostromskaya DV, Aidagulova SV, Kiselev RS, Volkov AM, Kobozev VV, Gaitan AS, Krivoshapkin AL, Grigorieva EV (2017) Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma. Tumour Biol 39:1010428317724282.  https://doi.org/10.1177/1010428317724282 CrossRefGoogle Scholar
  17. 17.
    Ranuncolo SM, Ladeda V, Specterman S, Varela M, Lastiri J, Morandi A, Matos E, Bal de Kier Joffe E, Puricelli L, Pallotta MG (2002) CD44 expression in human gliomas. J Surg Oncol 79:30–35; discussion 35–36Google Scholar
  18. 18.
    Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, Pai PC, Shin JW (2010) Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res 30:253–259Google Scholar
  19. 19.
    Klank RL, Decker Grunke SA, Bangasser BL, Forster CL, Price MA, Odde TJ, SantaCruz KS, Rosenfeld SS, Canoll P, Turley EA, McCarthy JB, Ohlfest JR, Odde DJ (2017) Biphasic dependence of glioma survival and cell migration on CD44 expression level. Cell Rep 18:23–31.  https://doi.org/10.1016/j.celrep.2016.12.024 CrossRefGoogle Scholar
  20. 20.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401.  https://doi.org/10.1038/nature03128 CrossRefGoogle Scholar
  21. 21.
    Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021.  https://doi.org/10.1158/0008-5472.CAN-04-1364 CrossRefGoogle Scholar
  22. 22.
    Yan Y, Zuo X, Wei D (2015) Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med 4:1033–1043.  https://doi.org/10.5966/sctm.2015-0048 CrossRefGoogle Scholar
  23. 23.
    Brown DV, Daniel PM, D’Abaco GM, Gogos A, Ng W, Morokoff AP, Mantamadiotis T (2015) Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget 6:6267–6280.  https://doi.org/10.18632/oncotarget.3365 Google Scholar
  24. 24.
    Brown DV, Filiz G, Daniel PM, Hollande F, Dworkin S, Amiridis S, Kountouri N, Ng W, Morokoff AP, Mantamadiotis T (2017) Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLoS ONE 12:e0172791.  https://doi.org/10.1371/journal.pone.0172791 CrossRefGoogle Scholar
  25. 25.
    Tanaka S, Nakada M, Yamada D, Nakano I, Todo T, Ino Y, Hoshii T, Tadokoro Y, Ohta K, Ali MA, Hayashi Y, Hamada J, Hirao A (2015) Strong therapeutic potential of gamma-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells. J Neurooncol 121:239–250.  https://doi.org/10.1007/s11060-014-1630-z CrossRefGoogle Scholar
  26. 26.
    Wang HH, Liao CC, Chow NH, Huang LL, Chuang JI, Wei KC, Shin JW (2017) Whether CD44 is an applicable marker for glioma stem cells. Am J Transl Res 9:4785–4806Google Scholar
  27. 27.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408.  https://doi.org/10.1006/meth.2001.1262 CrossRefGoogle Scholar
  28. 28.
    Miwa T, Nagata T, Kojima H, Sekine S, Okumura T (2017) Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer. Int J Oncol 51:771–780.  https://doi.org/10.3892/ijo.2017.4063 CrossRefGoogle Scholar
  29. 29.
    Kaaijk P, Troost D, Morsink F, Keehnen RM, Leenstra S, Bosch DA, Pals ST (1995) Expression of CD44 splice variants in human primary brain tumors. J Neurooncol 26:185–190CrossRefGoogle Scholar
  30. 30.
    Ariza A, Lopez D, Mate JL, Isamat M, Musulen E, Pujol M, Ley A, Navas-Palacios JJ (1995) Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum Pathol 26:1144–1147CrossRefGoogle Scholar
  31. 31.
    Ylagan LR, Quinn B (1997) CD44 expression in astrocytic tumors. Mod Pathol 10:1239–1246Google Scholar
  32. 32.
    Resnick DK, Resnick NM, Welch WC, Cooper DL (1999) Differential expressions of CD44 variants in tumors affecting the central nervous system. Mol Diagn 4: 219–232. 10.154/MODI00400219Google Scholar
  33. 33.
    Li H, Hamou MF, de Tribolet N, Jaufeerally R, Hofmann M, Diserens AC, Van Meir EG (1993) Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 53:5345–5349Google Scholar
  34. 34.
    Li H, Liu J, Hofmann M (1995) CD44 expression patterns in primary and secondary brain tumors. Zhonghua Yi Xue Za Zhi 75(525–528):573Google Scholar
  35. 35.
    Dajon M, Iribarren K, Cremer I (2017) Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. Immunobiology 222:89–100.  https://doi.org/10.1016/j.imbio.2016.06.009 CrossRefGoogle Scholar
  36. 36.
    Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, Wu A (2010) TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 10:415.  https://doi.org/10.1186/1471-2407-10-415 CrossRefGoogle Scholar
  37. 37.
    Li C, Ma L, Liu Y, Li Z, Wang Q, Chen Z, Geng X, Han X, Sun J, Li Z (2019) TLR2 promotes development and progression of human glioma via enhancing autophagy. Gene 700:52–59.  https://doi.org/10.1016/j.gene.2019.02.084 CrossRefGoogle Scholar
  38. 38.
    Jiang Y, Zhou J, Luo P, Gao H, Ma Y, Chen YS, Li L, Zou D, Zhang Y, Jing Z (2018) Prosaposin promotes the proliferation and tumorigenesis of glioma through toll-like receptor 4 (TLR4)-mediated NF-kappaB signaling pathway. EBioMedicine 37:78–90.  https://doi.org/10.1016/j.ebiom.2018.10.053 CrossRefGoogle Scholar
  39. 39.
    Qadri M, Almadani S, Jay GD, Elsaid KA (2018) Role of CD44 in regulating TLR2 activation of human macrophages and downstream expression of proinflammatory cytokines. J Immunol 200:758–767.  https://doi.org/10.4049/jimmunol.1700713 CrossRefGoogle Scholar
  40. 40.
    Svitkina TM (2018) Ultrastructure of the actin cytoskeleton. Curr Opin Cell Biol 54:1–8.  https://doi.org/10.1016/j.ceb.2018.02.007 CrossRefGoogle Scholar
  41. 41.
    Hohmann T, Dehghani F (2019) The cytoskeleton—a complex interacting meshwork. Cells.  https://doi.org/10.3390/cells8040362 Google Scholar
  42. 42.
    Zagzag D, Friedlander DR, Margolis B, Grumet M, Semenza GL, Zhong H, Simons JW, Holash J, Wiegand SJ, Yancopoulos GD (2000) Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 33:49–55.  https://doi.org/10.1159/000028975 CrossRefGoogle Scholar
  43. 43.
    Kwiatkowska A, Didier S, Fortin S, Chuang Y, White T, Berens ME, Rushing E, Eschbacher J, Tran NL, Chan A, Symons M (2012) The small GTPase RhoG mediates glioblastoma cell invasion. Mol Cancer 11:65.  https://doi.org/10.1186/1476-4598-11-65 CrossRefGoogle Scholar
  44. 44.
    Bourguignon LY (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18:251–259.  https://doi.org/10.1016/j.semcancer.2008.03.007 CrossRefGoogle Scholar
  45. 45.
    Chow MT, Luster AD (2014) Chemokines in cancer. Cancer. Immunol Res 2:1125–1131.  https://doi.org/10.1158/2326-6066.CIR-14-0160 Google Scholar
  46. 46.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444.  https://doi.org/10.1038/nature07205 CrossRefGoogle Scholar
  47. 47.
    Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G (2010) CX3CR47/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol 12:701–710.  https://doi.org/10.1093/neuonc/nop076 CrossRefGoogle Scholar
  48. 48.
    Ehtesham M, Winston JA, Kabos P, Thompson RC (2006) CXCR48 expression mediates glioma cell invasiveness. Oncogene 25:2801–2806.  https://doi.org/10.1038/sj.onc.1209302 CrossRefGoogle Scholar
  49. 49.
    Zhang J, Sarkar S, Yong VW (2005) The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. Carcinogenesis 26:2069–2077.  https://doi.org/10.1093/carcin/bgi183 CrossRefGoogle Scholar
  50. 50.
    Tang W, Wang X, Chen Y, Zhang J, Chen Y, Lin Z (2015) CXCL12 and CXCR50 as predictive biomarkers of glioma recurrence pattern after total resection. Pathol Biol 63:190–198.  https://doi.org/10.1016/j.patbio.2015.07.002 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurosurgery, Faculty of MedicineHokkaido UniversitySapporoJapan
  2. 2.Graduate School of Information Science and TechnologyHokkaido UniversitySapporoJapan
  3. 3.Shantou University Medical CollegeShantouChina

Personalised recommendations